Acorai is building a non-invasive heart failure monitoring platform with direct intracardiac pressure monitoring (ICPM) at its core. Acorai offers accurate and cost-efficient heart failure care using patented technology that leverages a novel combination of sensor technologies and machine learning to enable non-invasive ICPM, the only proven way to improve outcomes in HF patients. The device has been clinically validated, designated FDA Breakthrough Device and will be entering the market in 2025.  Acorai is a MedTech company with HQ in Sweden. The company has 20 FTE across 12 countries, with offices in Sweden and the UK.

Helsingborg, Sweden

Acorai

The Cedars-Sinai Accelerator helps today's technology innovators turn their ideas into breakthroughs. #CSAccelerator

Cedars-Sinai Accelerator

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining Cedars-Sinai Accelerator Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Cedars-Sinai Accelerator network as they come up.

You can always update this information later.

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Cedars-Sinai Accelerator company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Work for companies that improve the lives of healthcare professionals and patients